OR WAIT null SECS
Signal Rx Pharmaceuticals, Crystec, and ADYA Consulting are collaborating on the development of an inhaled dry powder formulation of SF2523 to treat pulmonary fibrosis, lung cancer, and SARS-CoV-2 related illnesses.
A collaboration between Signal Rx Pharmaceuticals, Crystec, and ADYA Consulting has been announced, in an Aug. 25, 2021 press release, for the development of an inhaled dry powder formulation of SF2523 to treat pulmonary fibrosis, lung cancer, and SARS-CoV-2 related illnesses.
SF2523 is a novel, small molecule dual PI3K-BRD4 inhibitor from Signal Rx, which works via a synergistic action on two pathways associated with the development of lung cancer and idiopathic pulmonary fibrosis (IPF). By inhibiting both the PI3K and BRD4 pathways, the cellular effect in tumor and fibrosis models is maximized and higher doses of the therapy can be tolerated.
As part of the collaboration, Crystec will employ its advanced modified supercritical antisolvent (mSAS) supercritical fluid particle engineering platform to achieve precise control of SF2523, while generating stable particles that are optimized for dry powder inhaled delivery at the same time. ADYA will support the accelerated development of the inhaled SF2523 formulation.
“We are excited to combine the unique therapeutic potential of SF2523 with the cutting-edge inhaled delivery capabilities of Crystec,” said Matt Williams, CEO of SignalRx, in the press release. “With support from ADYA, we hope to bring to the market a genuinely transformative drug for the treatment of lung cancer, fibrosis, as well as COVID-19 infection and its longer-term complications.”